Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [3] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics, aiming to improve therapeutic indices across various organs and tissues [3] - Entrada is advancing a diverse portfolio of RNA- and protein-based programs, particularly targeting neuromuscular and ocular diseases, with lead programs aimed at treating Duchenne muscular dystrophy [3] Recent Developments - On June 1, 2025, Entrada Therapeutics granted a total of 23,820 restricted stock units (RSUs) to six newly-hired non-executive employees as part of its 2025 Inducement Equity Plan [1] - The RSUs will vest incrementally, with one-fourth vesting on the one-year anniversary of the vesting commencement date, followed by quarterly vesting of 6.25% thereafter [2] - The inducement grants were approved by the Compensation Committee of the Board of Directors to incentivize new employees in accordance with Nasdaq Listing Rule 5635(c)(4) [1][2]